CJ Bioscience. Inc.

CJ Bioscience. Inc.

KKRX:311690
3,495.00
KRW
-50.00
(-1.41%)
-1,708.76EPS
56.97BMarket Cap

Total Valuation

KRW

As of June 30, 2026, CJ Bioscience. Inc. carries a market capitalization of 56.97B, placing it among publicly traded companies globally. Its enterprise value stands at 23.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap56.97B
Enterprise Value23.90B

Share Statistics

As of June 30, 2026, CJ Bioscience. Inc. has 13.07M shares outstanding.

Shares Outstanding13.07M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 15.49, and the price-to-book ratio stands at 1.36.

PS Ratio15.49
PB Ratio1.36
P/TBV Ratio1.90
P/FCF Ratio-2.87
P/OCF Ratio-2.88

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 6.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.90B versus a market cap of 56.97B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.50

Financial Position

As of June 30, 2026, CJ Bioscience. Inc. maintains a current ratio of 2.88, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.88, indicating elevated leverage, while an interest coverage ratio of -44.83 demonstrates limited ability to service its debt obligations.

Current Ratio2.88
Quick Ratio2.76
Debt / Equity18.88
Debt / EBITDA-0.41
Interest Coverage-44.83

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, CJ Bioscience. Inc. posted a negative return on equity (ROE) of -41.76, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.27, reflecting losses generated across the asset base. The company generates approximately 33.81M in revenue per employee across its workforce of 108.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 14.28 indicates how many times CJ Bioscience. Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-41.76
Return on Assets (ROA)-31.27
Revenue Per Employee33.81M
Employee Count108.75
Inventory Turnover14.28

Stock Price Statistics

KRW

As of the close on November 17, 2026, CJ Bioscience. Inc.'s stock has declined approximately 62.54% over the past 52 weeks. The 50-day moving average sits at 3,709.00, while the 200-day moving average is 5,638.23.

52-Week Price Change-62.54%
50-Day Moving Average3,709.00
200-Day Moving Average5,638.23

Income Statement

KRW

Over the twelve months ended June 30, 2026, CJ Bioscience. Inc. generated 3.68B in revenue and converted that into -22.33B in net income, yielding earnings per share of -1,708.76. EBITDA reached -19.15B, while operating income came in at -22.98B.

Revenue3.68B
Gross Profit785.36M
Operating Income-22.98B
Pretax Income-22.33B
Net Income-22.33B
EBITDA-19.15B
EBIT-22.98B
Earnings Per Share (EPS)-1,708.76

Balance Sheet

KRW

As of June 30, 2026, CJ Bioscience. Inc. holds 40.95B in cash and equivalents against 7.88B in total debt, resulting in a net debt position of 3.33B. Total book value stands at 41.75B, with working capital of 27.95B providing operational flexibility.

Cash & Cash Equivalents40.95B
Total Debt7.88B
Net Debt3.33B
Equity (Book Value)41.75B
Book Value Per Share3,195.10
Working Capital27.95B

Cash Flow

KRW

CJ Bioscience. Inc. produced -19.77B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -66.03M in capital expenditures, free cash flow totaled -19.83B - equivalent to -1,517.94 per share.

Operating Cash Flow-19.77B
Capital Expenditures-66.03M
Free Cash Flow-19.83B
FCF Per Share-1,517.94

Margins

Over the twelve months ended June 30, 2026, CJ Bioscience. Inc. posted a gross margin of 21.36, reflecting its pricing power and cost economics. The operating margin of -624.86 and net profit margin of -607.20 provide insight into operational efficiency.

Gross Margin21.36
Operating Margin-624.86
Pretax Margin-607.20
Profit Margin-607.20
EBITDA Margin-520.86

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -34.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 2.59, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to CJ Bioscience. Inc. shareholders.

Shareholder Yield2.59
FCF Yield-34.82

Stock Splits

CJ Bioscience. Inc.'s most recent stock split took place on July 7, 2023 with a 57:65 split ratio.

Last Split Date7/7/2023
Split Ratio57:65

Scores

As of June 30, 2026, CJ Bioscience. Inc. has an Altman Z-Score of -3.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-3.41